Recombinant FVIIa in the treatment of bleeding in acquired hemophilia

  title={Recombinant FVIIa in the treatment of bleeding in acquired hemophilia},
  author={Viviane Gu{\'e}rin and I. Chossat and Herv{\'e} Dutronc and M L Dubreuil and F Valentin},
  journal={American Journal of Hematology},
Recombinant Clotting Factors
Since their introduction, usage of each of the recombinant clotting factor concentrates has dramatically increased in countries where these products are licensed, available and affordable.
Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal
Recombinant activated coagulation FVIIa can circumvent the actions of inhibitory antibodies present in acquired haemophilia patients by directly activating FX on the surface of activated platelets at the site of injury (thereby bypassing FVIII and FIX).
Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired hemophilia A.
This case indicates important role of immunosuppressive therapy, which can rapidly induce a remission of this rare condition and be life-saving if introduced early in the course of illness and in doses higher than usually recommended.


Acquired haemophilia in the elderly is a severe disease: report of five new cases.
Five cases of acquired factor (F) VIII inhibitors diagnosed in the elderly population over a period of 5 years between 1995 and 1999 in the authors' hospital confirm and extends previous data reporting the complexity and severity of this disorder.
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
Recombinant factor VIIa was used to treat 38 patients with acquired haemophilia participating in the Novoseven compassionate-use program. 19 were male, median age 59, range 2-89 years. The median